The intravitreal injection of an anti-VEGF, a corticosteroid or a complement inhibitor for the treatment of potentially blinding retinal disease is today the most common procedure performed by an ophthalmologist.
We will approach 8 million intravitreal injections in 2023 and may hit 10 million by 2025.
There are about 1.75 million Americans with neovascular age-related macular degeneration, another 1.75 million with geographic atrophy, about 750,000 with diabetic macular edema and another 900,000 with retinal vein occlusion. One review article reported that just more than 3,000